Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Expands Proteomics Collaboration with Novartis

NEW YORK, July 25 (GenomeWeb News) - Cellzome said today that it has expanded a proteomics-based collaboration with Novartis that the companies initially entered in September 2004.


The expansion "is in line with the terms of the original agreement between the two companies," Cellzome said. 


Since September, Cellzome said it has mapped the protein networks of signaling pathways implicated in several therapeutic areas and has used this information to characterize various Novartis compounds. Under the terms of the expanded agreement, Cellzome said it will provide "more in-depth functional analyses of target candidates and signaling aspects of the disease pathways."


Novartis has made a "substantial equity investment" in Cellzome and will also contribute an undisclosed amount of research funding for two years with the option of extending the collaboration for a further two years, Cellzome said.


Terms of the agreement also include lead compound development options for both companies in exchange for licenses, milestone payments, and royalties.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.